Myriad Genetics announced a strategic partnership with jscreen, a national organization that delivers education and access to preventative genetic testing with a focus on high-risk populations. The collaboration combines the strengths of Myriad’s high-quality hereditary cancer and reproductive genetics products, MyRisk with RiskScore and Foresight Carrier Screen, with jscreen’s trusted education and genetic care navigation program. Through the partnership, the jscreen program intends to reach hundreds of thousands of high-risk adults across the United States through targeted outreach, educational events and in-person genetic screenings.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics, Flatiron partner to make genetic testing more accessible
- Myriad Genetics announces five research collaborations to study MRD testing
- Myriad Genetics and Ultima Genomics to explore UG 100 sequencing platform
- USPTO issues 3rd patent to Myriad aiding in bringing MRD assay to market
- Myriad Genetics initiated with an Equal Weight at Morgan Stanley